戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 have distinct selectivities for others (e.g. cimetidine).
2 ted with dexamethasone, diphenhydramine, and cimetidine.
3 ted with dexamethasone, diphenhydramine, and cimetidine.
4 m (MPP) and metformin and with the inhibitor cimetidine.
5                      Interventions: Systemic cimetidine.
6 ions such as 1-methyl-4-phenylpyridinium and cimetidine.
7  in rabbits in response to topically applied cimetidine.
8 3 with placebo and during period 2 with 0.5% cimetidine.
9 nist pyrilamine maleate or the H2 antagonist cimetidine.
10 -NAME plus pyrilamine maleate or l-NAME plus cimetidine.
11  by the histamine type-2 receptor antagonist cimetidine.
12 ch is important for the transport of PAH and cimetidine.
13 take of PAH and an 8-fold enhanced uptake of cimetidine.
14 trone sulfate as well as the basic compound, cimetidine.
15 , fipronil, strychnine, or the H2 antagonist cimetidine.
16 blocked by the histamine H2 receptor blocker cimetidine.
17  500 microM; piperonyl butoxide, 500 microM; cimetidine, 1 mM).
18            Furthermore, preadministration of cimetidine (100 microg; 5 microl; i.c.v.), the H2 histam
19 1%), famotidine (24%), sucralfate (24%), and cimetidine (12%).
20  treatment included sole treatment with oral cimetidine (15% vs 5%), topical interferon alfa-2b (0% v
21                   The H2 receptor antagonist cimetidine (2 microM) blocked the effects of lower conce
22           Neither the H2 receptor antagonist cimetidine (20 microM) nor the H3 receptor antagonist th
23 nd 40 mg each day thereafter) or intravenous cimetidine (300-mg bolus and 50 mg/hr thereafter) for up
24 ntihistamines (diphenhydramine, 1 mg/kg, and cimetidine, 4 mg/kg) or placebo before rapid vancomycin
25 al biopsy and cryotherapy with adjuvant oral cimetidine (8% vs 9%), and excisional biopsy and cryothe
26                                              Cimetidine (a gastric ADH inhibitor) reduced acetate pro
27 purpose of this study is to evaluate whether cimetidine, a histamine H2-receptor antagonist, interfer
28  experiment validating their prediction that cimetidine, a histamine-2 (H2) receptor agonist commonly
29 ntinuous summer sunlight were calculated for cimetidine, a pharmaceutical whose reaction with (1)O(2)
30  is the first case series demonstrating that cimetidine, a readily available oral medication, can be
31 As a control they also tested the effects of cimetidine against renal carcinoma, for which it was not
32 ese effects of histamine were antagonized by cimetidine, an H2 receptor antagonist, but not by select
33  Given that previous studies have shown that cimetidine, an SLC16A5-inhibitor, prevents murine cispla
34 was calculated separately for sucralfate and cimetidine and expressed as cost per bleeding episode av
35                Two pharmaceutical compounds (cimetidine and imipramine) and one new protease inhibito
36  significantly by organic cations, including cimetidine and N1-methylnicotinamide.
37 hereas an increased risk was associated with cimetidine and other histamine H2-receptor antagonists,
38 ion of impurities in drug substances such as cimetidine and rosiglitazone, using accurate mass tandem
39 ted additional CYP inhibitors and found that cimetidine and sulfaphenazole, two CYP inhibitors that h
40 tween erythromycin and cisapride, as well as cimetidine and terfenadine, were also reproduced.
41 ted with dexamethasone, diphenhydramine, and cimetidine and then treated with continuous intravenous
42 ition, with the cyanoguanidine side chain of cimetidine and tiotidine having the strongest influence.
43                                              Cimetidine and tiotidine were the best inhibitors, with
44 mbination therapy consisting of dapsone with cimetidine and vitamin E to enhance drug efficacy and fr
45 nd cryotherapy with or without adjuvant oral cimetidine and/or topical interferon alfa-2b provide sat
46                     Oxidation of ranitidine, cimetidine, and ciprofloxacin was primarily attributed t
47            Premedication with dexamethasone, cimetidine, and diphenhydramine is associated with a red
48 Burimamide, metiamide, cimetidine guanidine, cimetidine, and tiotidine were competitive with aldehyde
49          Prototype OCT inhibitors, including cimetidine, and type II cations (e.g., quinidine, quinin
50 the commonly used drugs: 1) metformin and 2) cimetidine; and two prototypic cationic substrates, 3) 1
51 e numerous drugs (topotecan, nitrofurantoin, cimetidine) as well as food carcinogens (2-amino-1-methy
52 ur cations, including MPP(+) , thiamine, and cimetidine, as substrates of SLC22A15.
53                               Application of cimetidine at all concentrations tested inhibited inflam
54 ith anti-Fx1A, the cytochrome P450 inhibitor cimetidine blocked an increase in catalytic iron and ROS
55 e suspected PFAPA syndrome, and treated with cimetidine, but cimetidine was not effective.
56 diphenhydramine, loratadine, ranitidine, and cimetidine, but has modest affinity for the H(2) recepto
57                                              Cimetidine, but not ranitidine, inhibits gastric alcohol
58  male rats received 100 mg/kg body weight of cimetidine (cimetidine group [CimG]) or saline solution
59 lfamethoxazole), poor membrane permeability (cimetidine, colchicine) and also affinity to efflux tran
60 urine volumes, urinary sodium excretion, and cimetidine-corrected creatinine clearance were compared.
61  treatment with antihistamines pyrilamine or cimetidine decreased lung weight and severity of pneumon
62                                              Cimetidine decreases bone loss through reduction of oste
63 t (pyrilamine) or an H2 receptor antagonist (cimetidine) demonstrated a protective effect of histamin
64                                  Improgan, a cimetidine derivative which lacks activity at known hist
65                                              Cimetidine, diclofenac, and miconazole, known inhibitors
66                                              Cimetidine exerts a beneficial effect on periodontal dis
67 e empirical data are needed on the uptake of cimetidine, fluoxetine, and gemfibrozil, and other ioniz
68 lfate for a better side effects profile, and cimetidine for cost-effectiveness.
69 y significantly increased (P = 0.016) in the cimetidine group (31.1 cells/subject) versus the placebo
70 orty-six male rats were distributed into the cimetidine group (CimG: received daily intraperitoneal i
71 eceived 100 mg/kg body weight of cimetidine (cimetidine group [CimG]) or saline solution (sham group
72 served in the cimetidine rinse group; in the cimetidine group, 63.4% of bacteria in the neutrophils w
73  bone level (P < 0.05) compared to the three cimetidine groups, with a marked decrease in inflammatio
74                       Burimamide, metiamide, cimetidine guanidine, cimetidine, and tiotidine were com
75 ydramine, whereas the H2 receptor antagonist cimetidine had no effect.
76                                     Although cimetidine had relatively small and variable effects on
77                                              Cimetidine has been shown to inhibit heme biosynthesis a
78        Vehicle or the H2 receptor antagonist cimetidine has no effect.
79                       Topical application of cimetidine in a liposome carrier for the prevention of p
80 small hydrophilic organic substrates PAH and cimetidine in comparison to the large hydrophobic organi
81  less than 2-fold enhanced uptake of PAH and cimetidine in comparison to wild-type rOAT3, which exhib
82 bleeding and more effective than intravenous cimetidine in maintaining gastric pH of >4 in critically
83 rcing the idea that the beneficial effect of cimetidine in PD may be due to reduction of IL-6 immunol
84 Objective: To describe the successful use of cimetidine in pediatric patients with EPP.
85      The limit of detection by SF-ICP-MS for cimetidine in solution was approximately 4-20 ng x g(-1)
86 port in the literature describing the use of cimetidine in the effective treatment of an adult patien
87 nger than 18 years and treated with systemic cimetidine in the past 3 years.
88 alog of the histamine H2 receptor antagonist cimetidine, induces antinociception after intraventricul
89  histological evidence that topically active cimetidine is a potent inhibitor of P. gingivalis-elicit
90                                              Cimetidine is a powerful H2 receptor antagonist that eli
91                                           As cimetidine is an H2 receptor antagonist, the authors hyp
92 .5% with omeprazole suspension and 6.8% with cimetidine, meeting the criteria for the noninferiority
93  500 mg of disulfiram (n = 6) or 2,000 mg of cimetidine (n = 2).
94                                The effect of cimetidine on ACHN derived tumors was not statistically
95             Additional studies of the use of cimetidine on osteoporosis and osteoporotic fractures ar
96 icantly attenuated compared with control and cimetidine only sites (P < 0.05).
97 tment with either the H2 receptor antagonist cimetidine or with the potassium channel blocker tetraet
98 sed risks were also observed with the use of cimetidine (OR 2.5, 95% CI 1.4-4.6) and psychotropic dru
99 al injections of 100 mg/kg of body weight of cimetidine) or the saline group (SG).
100 e studies provide evidence that topical 0.5% cimetidine oral rinse enhances the antibacterial functio
101 ent with dexamethasone, diphenhydramine, and cimetidine, patients received paclitaxel at a dose of 25
102                                              Cimetidine (pK(a) 6.92), a competitive inhibitor of hOCT
103  analog of the histamine receptor antagonist cimetidine, produces highly effective analgesia followin
104  Improgan, a congener of the H(2) antagonist cimetidine, produces non-opioid antinociception which is
105 he suppression was blocked by picrotoxin and cimetidine, respective antagonists to lobster GABA and h
106 hat the inhibition of A549 derived tumors by cimetidine resulted in a statistically significant effec
107 36) in bacterial killing was observed in the cimetidine rinse group; in the cimetidine group, 63.4% o
108  conducted to examine the effects of topical cimetidine rinse on neutrophil function in the gingival
109 ects rinsed twice a day with placebo or 0.5% cimetidine rinses.
110  between the l-NAME and combined l-NAME plus cimetidine sites but these sites were significantly atte
111 l sites was not significantly different from cimetidine sites.
112      In the sulfur-containing drug substance cimetidine, structurally related impurities well below t
113 Improgan is an analog of the H(2) antagonist cimetidine that does not act on known histamine receptor
114                  Improgan is a derivative of cimetidine that induces non-opioid antinociception after
115 However, i.v. or i.c.v. preadministration of cimetidine, the H2-histamine receptor antagonist, failed
116         Excisional biopsy, cryotherapy, oral cimetidine, topical or injection interferon alfa-2b, and
117 35, Y341, and F362 are important for PAH and cimetidine transport by rOAT3.
118                               hOCT2-mediated cimetidine transport decreased over this pH range, the c
119 rved that the residues contribute to PAH and cimetidine transport in different ways: the -OH group of
120 suspension treatment and on 50% of days with cimetidine treatment (p < .001, all trial days).
121 rial with parallel omeprazole suspension and cimetidine treatment groups.
122                                We found that cimetidine treatment in a xenograft model using A549 lun
123                                              Cimetidine treatment in a xenograft model using ACHN ren
124 cy, the cost per bleeding episode averted of cimetidine was 6.5-fold greater than the cost per bleedi
125           Complete removal of ranitidine and cimetidine was achieved within 30 min of electrolysis at
126 A syndrome, and treated with cimetidine, but cimetidine was not effective.
127                As the H2 receptor antagonist cimetidine was perfused to the tissue, histamine levels
128           The Ki value of the E3 isozyme for cimetidine was the same as the in vitro dissociation con
129  salt), differently melt-quenched samples of cimetidine were also analyzed.
130 ndent sample of 14 patients (seven receiving cimetidine) were mixed with 60 mL of enteral feeding in
131 secretory dose of omeprazole, ranitidine, or cimetidine, were intragastrically administered saline, a
132 on, which were reversed by the H2 antagonist cimetidine, were observed in PBMC and isolated monocytes
133 played markedly reduced transport of TEA and cimetidine while retaining transport of 1-methyl-4-pheny

 
Page Top